Austin Aerts Sells Shares of SERA $SERA

Key Points

  • Austin Aerts sold 2,037 shares of Sera Prognostics, Inc. ($SERA) worth $4,094.37.
  • $SERA last traded around $1.91.

Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.

Austin Aerts, Chief Financial Officer at Sera Prognostics, Inc. ($SERA), sold 2,037 shares at an average price of $2.01, for a total transaction of $4,094.37. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Sera Prognostics, Inc. Stock Down 8.0%

Shares of Sera Prognostics, Inc. ($SERA) traded around $1.91 on Monday, down 8.0% for the day.

Last price$1.91
Market cap$83.63M
Forward P/E-3.96
Beta0.98
52-week low$1.56
52-week high$3.95
50-day MA$2.01
200-day MA$2.40
Current ratio1.98
Quick ratio1.91
Debt-to-equity0.05

Sera Prognostics, Inc. Earnings

EPS (ttm)-$0.68
Revenue (ttm)$70K
Revenue growth76.50%
Net margin0%
Return on equity-45.03%
Next earningsNov 16, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$5.50
High target$6
Low target$5
Analysts covering2

About Sera Prognostics, Inc.

Sera Prognostics, Inc., a women's health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

ExchangeNasdaqGM
SectorHealthcare
IndustryMedical Devices
HeadquartersSalt Lake City, UT
CEOMs. Zhenya Lindgardt M.B.A.
Employees71

Get Sera Prognostics, Inc. alerts

New 13F filings, insider trades, and analyst moves on $SERA, sent to your inbox. Free, and you can unsubscribe anytime.

This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.